Jaya Krishna Chintanaboina, MD
Gastroenterology · Fresno, CANPI 1144478454
Payments from drug & device makers
What this record shows
This record is dominated by grants: $52,500 of the $56,675 with a category attached, or 92.6%. Pfizer accounts for 70.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $53,023 and has fallen 97.8% since, to $1,187 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $347.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$40K
- Boston Scientific$14K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$313
- Covidien LP$275
- Johnson & Johnson$230
- plus $635 from 13 others
What the payments were for
- Grants$52,50093%
- Travel & lodging$1820%
- Food & beverage$3,9937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $40,000 |
| Boston Scientific | 39 | $14,112 |
| AbbVie | 59 | $1,110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $313 |
| Covidien LP | 4 | $275 |
| Johnson & Johnson | 10 | $230 |
| Phathom Pharmaceuticals, Inc. | 10 | $145 |
| Ardelyx, Inc. | 6 | $101 |
| Madrigal Pharmaceuticals | 4 | $94 |
| Olympus America Inc. | 2 | $71 |
| Celltrion USA Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Lilly USA, LLC | 1 | $26 |
| Novo Nordisk | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - BILIARY DEVICES$12,500
- AXIOS$181
- Barrx$163
- EXALT$124
How this compares
$56,675 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 11 | $70,802 |
| LinzessLinaclotide | 16 | $8,678 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 235 | $3,933 |
| Pantoprazole Sodium | 325 | $2,996 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 177 | $2,903 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 19 | $2,742 |
| Budesonide EcBudesonide | 12 | $2,086 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 79 | $1,290 |
| Omeprazole | 55 | $776 |
| Clarithromycin | 24 | $722 |
| Famotidine | 18 | $280 |
| Amoxicillin | 24 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,110 | $8,67816 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $313 | $2,74219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Fresno
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.